From Wikipedia, the free encyclopedia
Jump to: navigation, search

Oncomatryx Biopharma S. L. is a pharmaceutical biotechnology company that develops personalized treatments against invasive cancer as well as tests for its early detection. Established by Laureano Simón, PhD, Oncomatryx thus engages twofold in the fight against invasive kinds of cancer, such as pancreatic cancer or invasive breast cancer, all of which have high mortality rates.

Oncomatryx's research focuses on peritumoral stroma, which has been found to take part in promoting cancer invasiveness and curtailing treatment efficacy.[1]

Laureano Simón[edit]

Laureano Simón began his business career in 2000 with the creation of Progenika Biopharma S.A., a personalized medicine company which was acquired by Grifols in February 2013.[2]

Dr. Simón holds a Ph.D. in Chemical Sciences (Molecular Biology) by the Universidad Autónoma de Madrid, a Master’s degree in Biotechnology by the University of Navarra, an MSc by the “University of Wisconsin-Madison” and a Bachelor’s degree in Pharmacy by the University of Santiago de Compostela. He has patented, among others, clinical products such as BLOODchip and LIPOchip. He has also published many articles in scientific journals and has received several awards throughout his career, among which it is worth noting European Eurowards Entrepreneurship Award in 2004, Ernst & Young’s Most Innovative Entrepreneur of the Year in 2010 and Ruban D´Honneur of the European Business Awards -HSBC Bank in 2011. He has participated in science and technology development plans from both the Spanish and the Basque Governments and has contributed to several private foundations, like the Carlos Slim Institute of Health, the Fundación Pedro Barrié de la Maza and the BBVA Foundation.

Research and development[edit]

The company bases its R&D on the recent discovery that tumor cells generate changes in the cells that surround them as well as in the extracellular matrix, facilitating invasion metastases.[3][4] Oncomatryx and its collaborators and advisors have proved that peritumoral stroma, which is constituted by mesenchymal cells and extracellular matrix, plays a key role in tumor invasiveness and metastasis, at the same time being a physical barrier that prevents anti-cancer agents from reaching tumor cells.[5][6][7][8][9][10][11][12][13][14][15][16][17][18]

Oncomatryx is developing a new generation of biological anti-tumor drugs, combining cytotoxic molecules and monoclonal antibodies specifically directed towards tumor associated stroma.

Scientific Advisory Board[edit]

  • Franco Dosio, Ph.D. Professor, Department of Drug Science and Technology. Università degli Studi di Torino. Torino, Italy.
  • Tomás Girbés, Ph.D. Professor. Departament of Nutrition and Bromatology. Facultad de Medicina. Universidad de Valladolid, CINAD. Valladolid, Spain.
  • Manuel Hidalgo, M.D., Ph.D. Head of Gastrointestinal Cancer Clinical Research unit. Centro Nacional de Investigaciones Oncológicas. Madrid, Spain.
  • Roland E. Kontermann, Ph.D. Mildred-Scheel Professor. Biomedical Engineering unit. Institut für Zellbiologie und Immunologie. Universität Stuttgart. Germany.
  • Klaus Pfizenmaier, Ph.D. Professor, Director of Institute. Cell Biology unit. Institut für Zellbiologie und Immunologie. Universität Stuttgart. Germany.
  • Andrea Bolognesi, Phd. Professor. Department of Experimental Diagnosticand Speciality Medicine. Universitá Bologna, Italy.


Oncomatryx collaborates with the Institut für Zell Biologie und Immunologie of the University of Stuttgart,[19][20] the University of Valladolid, Hospital Universitario Marqués de Valdecilla, Hospital Universitario Central de Asturias, the Centro Nacional de Investigaciones Oncológicas, National Jewish Health and Breast Cancer Research among others.

Developments and products of the company[edit]

Diagnostic tests[edit]

Currently, invasive cancer is associated with a very short life expectancy . In the case of pancreatic cancer, which unfortunately is almost always already in invasive stages at the time of diagnosis, only between 1% and 4% of patients survive for five years after diagnosis.[21]

Oncomatryx has developed molecular diagnostic tests to predict the invasiveness of breast tumors (DMTXbreastScan) and pancreas, colon, lung, and head and neck tumors (DMTXinvaScan). These tests have already been used successfully in hospitals in Andalucia, Asturias, Cantabria, Catalonia, Galicia, Madrid, Navarre, the Basque Country and Valencia in Spain. In addition, the universities of Columbia (USA), Munich (Germany) and Copenhagen (Denmark) have also proven their high sensitivity and specificity. DMTXinvaScan and DMTXbreastScan were presented to the international medical community at the Annual Conference of the United States and Canadian Academy of Pathology, held in Baltimore, USA, in March 2013. Specifically, DMTXbreastScan helps to determine, at the moment of first diagnosis, if a breast tumor has the capacity to develop metastases. This test, which is already being used in USA hospitals such as Johns Hopkins Hospital in Baltimore and Cedars Sinai Hospital in Los Angeles, has 93.5% sensitivity and 94.2% specificity in detecting invasive breast tumors in biopsies. In addition, it helps to predict if a benign lesion of the breast, such as a papilloma, will turn into a malignant tumor, so the treatment can be adapted more effectively for each patient.[22][23]

Antitumor treatments[edit]

Antitumor drugs developed by Oncomatryx, which specifically target the peritumoral stroma, are currently in pre-clinical development phase and will enter clinical trials in 2015. For this purpose, the company has reached an agreement with the U.S. National Jewish Health hospital and Case Western Reserve University [24][25][26] whereby Oncomatyx will use a human protein, Cystatin-C, as a principle asset for the development of drugs against invasive breast cancer.

Oncomatryx has also signed collaboration agreements with the Universität Stuttgart (Germany), the Universidad de Valladolid (Spain), and other biotech companies for the development of immunotoxins and ADCs targeted specifically towards the stromal component of tumors. This strategy allows for attacking directly the cells responsible for invasion and metastasis in cancer. These immunotoxins and ADCs are specifically directed against two proteins, known as MTX1 and MTX2, which are expressed only in the peritumoral stroma that surround the tumor and facilitates its progression and metastasis.[27]


  1. ^ Chiang, Anne C.; Massagué, Joan (2008). "Molecular Basis of Metastasis". New England Journal of Medicine. 359 (26): 2814–2823. PMC 4189180Freely accessible. PMID 19109576. doi:10.1056/NEJMra0805239. 
  2. ^ Biospace.com
  3. ^ Mahadevan, D.; von Hoff, D. D. (2007). "Tumor-stroma interactions in pancreatic ductal adenocarcinoma". Molecular Cancer Therapeutics. 6 (4): 1186–1197. PMID 17406031. doi:10.1158/1535-7163.MCT-06-0686. 
  4. ^ Ostermann, E.; Garin-Chesa, P.; Heider, K. H.; Kalat, M.; Lamche, H.; Puri, C.; Kerjaschki, D.; Rettig, W. J.; Adolf, G. R. (2008). "Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts". Clin. Cancer Research. 14 (14): 4584–4592. doi:10.1158/1078-0432.CCR-07-5211. 
  5. ^ Girbés, T.; Citores, Luc�a; Miguel Ferreras, J.; Angeles Rojo, M.; Iglesias, Rosario; Mu�Oz, Raquel; Javier Arias, F.; Calonge, Margarita; Ram�n Garc�a, J.; m�Ndez, Enrique (1993). "Isolation and partial characterization of nigrin b, a non-toxic novel type 2 ribosome-inactivating protein from the bark of Sambucus nigra L". Plant Molecular Biology. 22 (6): 1181–1186. PMID 8400135. doi:10.1007/BF00028990.  replacement character in |last9= at position 4 (help); replacement character in |last10= at position 2 (help); replacement character in |first2= at position 4 (help); replacement character in |last6= at position 3 (help)
  6. ^ Muñoz, R.; Arias, Y; Ferreras, J. M.; Rojo, M. A.; Gayoso, M. J.; Nocito, M; Benitez, J; Jiménez, P; Bernabéu, C; Girbés, T (2007). "Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b". Cancer Lett. 256 (1): 73–80. PMID 17637501. doi:10.1016/j.canlet.2007.05.012. 
  7. ^ Ferreras, José Miguel; Citores, Lucía; Iglesias, Rosario; Jiménez, Pilar; Souza, Aíla Maria; Gayoso, Manuel José; Girbés, Tomás (2011). "Occurrence and new procedure of preparation of nigrin, an antiribosomal lectin present in elderberry bark". Food Research International. 44 (9): 2798–2805. doi:10.1016/j.foodres.2011.06.004. 
  8. ^ Ferreras, José M.; Citores, Lucía; Iglesias, Rosario; Jiménez, Pilar; Girbés, Tomás (2011). "Use of Ribosome-Inactivating Proteins from Sambucus for the Construction of Immunotoxins and Conjugates for Cancer Therapy". Toxins. 3 (12): 420–441. doi:10.3390/toxins3050420. 
  9. ^ Mersmann, Michael; Schmidt, Alexej; Rippmann, J�rg F.; w�Est, Thomas; Brocks, Bodo; Rettig, Wolfgang J.; Garin-Chesa, Pilar; Pfizenmaier, Klaus; Moosmayer, Dieter (2001). "Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas". International Journal of Cancer. 92 (2): 240–248. doi:10.1002/1097-0215(200102)9999:9999<::AID-IJC1170>3.0.CO;2-U.  replacement character in |last4= at position 2 (help); replacement character in |first3= at position 2 (help)
  10. ^ Brocks, B; Garin-Chesa, P; Behrle, E; Park, J. E.; Rettig, W. J.; Pfizenmaier, K; Moosmayer, D (2001). "Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse". Molecular Medicine. 7 (7): 461–469. PMC 1950057Freely accessible. PMID 11683371. 
  11. ^ Schmidt, Alexej; Müller, Dafne; Mersmann, Michael; Wüest, Thomas; Gerlach, Elke; Garin-Chesa, Pilar; Rettig, Wolfgang J.; Pfizenmaier, Klaus; Moosmayer, Dieter (2001). "Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection". European Journal of Biochemistry. 268 (6): 1730–1738. PMID 11248693. doi:10.1046/j.1432-1327.2001.02046.x. 
  12. ^ Völkel, T.; Müller, Rolf; Kontermann, Roland E (2004). "Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library". Biochemical and Biophysical Research Communications. 317 (2): 515–521. PMID 15063787. doi:10.1016/j.bbrc.2004.03.074. 
  13. ^ Rüger, R.; Müller, Dafne; Fahr, Alfred; Kontermann, Roland E. (2006). "In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes". J. of Drug Targeting. 14 (8): 576–582. doi:10.1080/10611860600864018. 
  14. ^ Baum, P.; Müller, Dafne; Rüger, Ronny; Kontermann, Roland E. (2007). "Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells". J. of Drug Targeting. 15 (6): 399–406. doi:10.1080/10611860701453034. 
  15. ^ Müller, D.; Trunk, Gerhard; Sichelstiel, Anke; Zettlitz, Kirstin A.; Quintanilla, Miguel; Kontermann, Roland E. (2008). "Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice". J. Of Immun. Methods. 339 (1): 90–98. PMID 18790696. doi:10.1016/j.jim.2008.08.008. 
  16. ^ Sokol, J.P.; Schiemann, W. P. (2004). "Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells". Mol Cancer Res. 2 (3): 183–195. PMID 15037657. 
  17. ^ Sokol, J.P.; Neil, J. R.; Schiemann, B. J.; Schiemann, W. P. (2005). "The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta". Breast Cancer Res. 7 (5): R844–53. PMC 1242164Freely accessible. PMID 16168131. doi:10.1186/bcr1312. 
  18. ^ Tian, M.; Schiemann, W. P. (2009). "Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer". Transl Oncol. 2 (3): 174–183. PMC 2730134Freely accessible. PMID 19701502. 
  19. ^ Business Wire
  20. ^ http://www.clinicaspace.com/News/oncomatrix-signs-an-agreement-with-the-university/281846 ClinicaSpace
  21. ^ "Oncomatrix designs a test that shows if breast cancer will metastasize". Spaintechnology.com. 2013-07-25. Retrieved 2014-04-13. 
  22. ^ Business Wire
  23. ^ Clinicaspace
  24. ^ http://www.businesswire.com/news/home/20120619006072/en/Oncomatrix-National-Jewish-Health-Case-Western-Reserve#.U0QXMjiKC1s Businesswire
  25. ^ Biospace
  26. ^ Biotech Finances
  27. ^ "Oncomatrix Signs an Agreement with the University of Stuttgart to Develop New Drugs for Treating Tumor Metastases". FierceBiotech. Retrieved 2014-04-13.